Neoplasm Metastasis

122 treatments and conditions followed through the public trial records. Not medical advice. How a status is set

Lists the pairs whose condition is this category or one beneath it. A category is not a diagnosis and not advice.

Broader: Neoplasms

Narrower: Neoplasms, Unknown Primary 2, Neoplastic Cells, Circulating 3

Treatments and conditions

Neoplasm Metastasis
Treatment and conditionWhere it standsTrials
186RNL for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Abemaciclib for neoplasm metastasisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Abemaciclib + Irinotecan + Temozolomide for neoplasm metastasisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Ablative Prostate Boost + Androgen Deprivation Therapy (ADT) + Androgen Receptor Pathway Inhibitors (ARPIs) + Higher Nodal Dose Escalation + Ultrahypofractionated Whole-Pelvis Radiotherapy for neoplasm metastasisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Ablative Prostate Boost + Androgen Deprivation Therapy (ADT) + Androgen Receptor Pathway Inhibitors (ARPIs) + Intermediate Nodal Dose Escalation + Ultrahypofractionated Whole-Pelvis Radiotherapy for neoplasm metastasisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Anastrozole placebo + Letrozole placebo + CAMIZESTRANT for neoplasm metastasisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Androgen Deprivation Therapy (ADT) + Androgen Receptor Pathway Inhibitors (ARPIs) + Higher Nodal Dose Escalation + SBRT-Based Prostate Radiotherapy (No Boost) + Ultrahypofractionated Whole-Pelvis Radiotherapy for neoplasm metastasisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Androgen Deprivation Therapy (ADT) + Androgen Receptor Pathway Inhibitors (ARPIs) + Intermediate Nodal Dose Escalation + SBRT-Based Prostate Radiotherapy (No Boost) + Ultrahypofractionated Whole-Pelvis Radiotherapy for neoplasm metastasisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
ART6043 for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
ART6043 + Olaparib for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
ASP3082 for neoplasm metastasisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Atezolizumab for neoplasm metastasisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
ATEZOLIZUMAB + Divarasib for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
AVB-001 (Dose Escalation Phase) + AVB-001 (Dose Expansion Phase) for neoplasm metastasisTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
Axelopran + pembrolizumab for neoplasm metastasisTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
BEVACIZUMAB + Divarasib for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biopsy for neoplasm metastasisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biopsy Procedure + Biospecimen Collection + Echocardiography Test + Multigated Acquisition Scan + Radiologic Imaging Procedure + PIDNARULEX + TRASTUZUMAB DERUXTECAN for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Capecitabine for neoplasm metastasisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Capecitabine + pembrolizumab for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Capivasertib for neoplasm metastasisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Carboplatin for neoplasm metastasisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Carboplatin + ELRAGLUSIB for neoplasm metastasisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Carboplatin + ELRAGLUSIB + Paclitaxel for neoplasm metastasisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Carboplatin-Paclitaxel for neoplasm metastasisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cisplatin for neoplasm metastasisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Counseling + Questionnaire Administration + Psilocybin for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
CP-383 for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
CR-002 for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Daraxonrasib for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)2
Datopotamab Deruxtecan for neoplasm metastasisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)2
Digoxin for neoplastic cells, circulatingPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Divarasib for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Divarasib + Cetuximab for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Divarasib + ERLOTINIB for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Divarasib + Inavolisib for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Dostarlimab for neoplasm metastasisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Doublet Chemotherapy, Dose-reduced (75%) for neoplasm metastasisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Doxorubicin hydrochloride + ELRAGLUSIB for neoplasm metastasisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
DURVALUMAB + Datopotamab Deruxtecan for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Echocardiography Test + Doxorubicin hydrochloride for neoplasm metastasisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Elironrasib for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Elironrasib + Daraxonrasib for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Elraglusib for neoplasm metastasisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
ELRAGLUSIB + Gemcitabine Hydrochloride for neoplasm metastasisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
ELRAGLUSIB + NAB-PACLITAXEL + Gemcitabine Hydrochloride for neoplasm metastasisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
ENABLE Cornerstone for neoplasm metastasisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
FMC-376 for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Folfoxiri for neoplastic cells, circulatingPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Fulvestrant + CDK4/6i + Capivasertib for neoplasm metastasisTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Gemcitabine Hydrochloride for neoplasm metastasisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
GI-102 for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
GI-102 + BEVACIZUMAB + Paclitaxel for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
GI-102 + Doxorubicin for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
GI-102 + Eribulin for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
GI-102 + PEMBROLIZUMAB for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
GI-102 + TRASTUZUMAB DERUXTECAN for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
GI-102 subcutaneous (SC) for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
GI-108 for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Hafnium Oxide-containing Nanoparticles NBTXR3 + Radiation Therapy for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Hybrid Palliative Radiation Therapy for neoplasm metastasisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Irinotecan + ELRAGLUSIB for neoplasm metastasisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Irinotecan + Temozolomide for neoplasm metastasisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Irinotecan hydrochloride + bevacizumab for neoplasm metastasisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
IRINOTECAN HYDROCHLORIDE + BEVACIZUMAB + LEUCOVORIN + Fluorouracil for neoplasm metastasisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Iscador*P for neoplasm metastasisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Ivonescimab for neoplasm metastasisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Local Therapy + Standard Therapy for neoplasm metastasisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Loco-regional radiotherapy for neoplasm metastasisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Lomustine + ELRAGLUSIB for neoplasm metastasisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN for neoplasm metastasisTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
METAREM is a master protocol that encompasses multiple therapeutic sub-protocols, each involving distinct interventions. Accordingly, the description of the intervention will be specified within each for neoplasm metastasisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Migoprotafib + Divarasib for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
ML-016 for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Molecularly matched therapy for neoplasm metastasisTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Monotherapy, Dose-reduced (75%) for neoplasm metastasisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
N17350 for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Nab-paclitaxel for neoplasm metastasisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Nab-paclitaxel + Gemcitabine + VCN-01 oncolytic adenovirus (zabilugene almadenorepvec) for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Neoadjuvant chemotherapy instead of upfront surgery for neoplastic cells, circulatingPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
NIMOTUZUMAB + Ivonescimab for neoplasm metastasisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Niraparib for neoplasm metastasisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Nivolumab & Ipilimumab + Zirdafulven for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
NSAI + CDK4/6i + Capivasertib for neoplasm metastasisTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Oleclumab for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
OR502 + CEMIPLIMAB for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
OSIMERTINIB + Patritumab Deruxtecan for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Osimertinib + Savolitinib for neoplasm metastasisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Paclitaxel for neoplasm metastasisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Panitumumab for neoplasm metastasisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Patritumab Deruxtecan for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)2
PD-1 Inhibitors + Mitoxantrone Hydrochloride for neoplasm metastasisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
PD1+ TILs (NUMARZU-001) product infusion for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Pembrolizumab for neoplasm metastasisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
PEMBROLIZUMAB + Paclitaxel for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Pemetrexed/Carboplatin + Pemetrexed/Cisplatin for neoplasm metastasisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
PET/CT + FLUDEOXYGLUCOSE F-18 + [18F]-FAPI-74 for neoplasm metastasisTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Ponsegromab for neoplasm metastasisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
prifetrastat in combination with fulvestrant for neoplasm metastasisTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
prifetrastat monotherapy for 15 days then combination with fulvestrant for neoplasm metastasisTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Prophylactic External Beam Radiotherapy for neoplasm metastasisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Psychotherapy + Survey Administration + Psilocybin for neoplasm metastasisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Puxitatug Samrotecan for neoplasm metastasisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
S-1 + Irinotecan for neoplasm metastasisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Sacituzumab tirumotecan for neoplasm metastasisTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Savolitinib + Placebo for neoplasm metastasisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Sbrt for neoplasm metastasisTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Spartalizumab for neoplasms, unknown primaryPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Telisotuzumab vedotin for neoplasm metastasisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tersolisib for neoplasm metastasisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tislelizumab for neoplasms, unknown primaryPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Trametinib + Doxorubicin + CISPLATIN + Gefitinib + Disulfiram + SUNITINIB + Methotrexate for neoplasm metastasisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Trametinib + Gefitinib + Disulfiram + Ifosfamide + SUNITINIB for neoplasm metastasisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Trastuzumab deruxtecan for neoplasm metastasisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
TYRA-300 for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
VMD-928 100 mg Tablet for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
VMD-928 Tablet and Pembrolizumab (200 mg) for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Xiaochaihu Granules (Low Dose) for neoplasm metastasisTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
XON7 for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Zidesamtinib (NVL-520) for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Zirdafulven for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Zirdafulven + Olaparib for neoplasm metastasisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1

Categories are from Medical Subject Headings (MeSH), U.S. National Library of Medicine, courtesy of the U.S. National Library of Medicine: MeSH. They may not reflect the most current data available from NLM. NLM does not endorse this site.